Client Overview
The client is an innovative drug research and development company pursuing interactions with the US FDA during early development. The company lacked prior experience in preparing and submitting Type B Pre-IND meeting requests and associated meeting packages.
Client Background
As the client advanced its development program, a well-prepared Pre-IND interaction became essential to gain Regulatory clarity. However, limited internal submission experience created uncertainty around package preparation, meeting content, and the probable nature of agency responses.
Services in Scope
Preparation of Type B Pre-IND meeting request documentation.
Compilation and submission of the meeting package to the US FDA.
Publishing and submission support for NDA, MAA, IND, and DMF packages.
CMC-focused support to strengthen the content and structure of the submission.
Regulatory guidance on likely health authority expectations and responses.
Challenges
No prior Regulatory experience in Type B Pre-IND submissions.
Need to build a complete, submission-ready meeting package for the US FDA.
Requirement for a clearer understanding of probable HA questions and responses before formal interaction.
Solution
Freyr provided focused Regulatory and CMC support to build a structured, submission-ready meeting package. The team helped the client understand both the technical expectations of the submission and the likely direction of FDA feedback, improving preparedness for the Pre-IND meeting process.
1
Assessed the client’s development context and Pre-IND objectives to frame the meeting request appropriately.
2
Compiled and prepared the Type B Pre-IND meeting package for submission to the US FDA.
3
Applied CMC expertise to strengthen package quality and submission completeness.
4
Guided the client on probable health authority responses to improve Regulatory readiness.
Impact
- Enabled timely preparation and submission of the Type B Pre-IND meeting package.
- Improved the client’s understanding of FDA expectations ahead of the interaction.
- Strengthened internal confidence in managing early-stage Regulatory submissions.
This engagement shifted the client from a limited submission to a more informed Pre-IND interaction, enhancing the technical quality and understanding of agency expectations. The outcome was a stronger Regulatory foundation for future milestones.
